ロード中...

Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells

FDA approval of new therapies in 2011 has greatly expanded the treatment options for metastatic melanoma. Patients with V600 mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) positive metastatic melanoma are now treated with the RAF inhibitor, vemurafenib (Zelboraf) as a first line thera...

詳細記述

保存先:
書誌詳細
主要な著者: Basile, Kevin J, Aplin, Andrew E
フォーマット: Artigo
言語:Inglês
出版事項: e-Century Publishing Corporation 2012
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3512187/
https://ncbi.nlm.nih.gov/pubmed/23226618
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!